China views the U.S. as its main geopolitical rival, highlighting Washington’s allies, particularly Japan and the Philippines, in South China Sea military activities. Analysts suggest increasing...
China’s AI-driven drug firms are expanding globally despite U.S. scrutiny. They secured $93 billion in licensing deals in 2026, a significant rise. Metis TechBio struck a...
China’s decision to set a reduced GDP growth target of 4.5–5.0 per cent for 2026 marks another step in a long-running structural transition. Chinese policymakers have...